BHVN
Price
$22.85
Change
+$0.40 (+1.78%)
Updated
May 2 closing price
Capitalization
2.33B
5 days until earnings call
DMAC
Price
$4.23
Change
+$0.10 (+2.42%)
Updated
May 2 closing price
Capitalization
181.28M
16 days until earnings call
Ad is loading...

BHVN vs DMAC

Header iconBHVN vs DMAC Comparison
Open Charts BHVN vs DMACBanner chart's image
Biohaven
Price$22.85
Change+$0.40 (+1.78%)
Volume$2.1M
Capitalization2.33B
DiaMedica Therapeutics
Price$4.23
Change+$0.10 (+2.42%)
Volume$124.62K
Capitalization181.28M
BHVN vs DMAC Comparison Chart
Loading...
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHVN vs. DMAC commentary
May 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a StrongBuy and DMAC is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 05, 2025
Stock price -- (BHVN: $22.85 vs. DMAC: $4.23)
Brand notoriety: BHVN and DMAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 124% vs. DMAC: 141%
Market capitalization -- BHVN: $2.33B vs. DMAC: $181.28M
BHVN [@Biotechnology] is valued at $2.33B. DMAC’s [@Biotechnology] market capitalization is $181.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green whileDMAC’s FA Score has 0 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • DMAC’s FA Score: 0 green, 5 red.
According to our system of comparison, DMAC is a better buy in the long-term than BHVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 4 TA indicator(s) are bullish while DMAC’s TA Score has 4 bullish TA indicator(s).

  • BHVN’s TA Score: 4 bullish, 4 bearish.
  • DMAC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BHVN and DMAC are a good buy in the short-term.

Price Growth

BHVN (@Biotechnology) experienced а +15.17% price change this week, while DMAC (@Biotechnology) price change was +4.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.30%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was -4.75%.

Reported Earning Dates

BHVN is expected to report earnings on Aug 04, 2025.

DMAC is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BHVN($2.33B) has a higher market cap than DMAC($181M). DMAC YTD gains are higher at: -22.099 vs. BHVN (-38.822). DMAC has higher annual earnings (EBITDA): -24.07M vs. BHVN (-877.26M). BHVN has more cash in the bank: 486M vs. DMAC (50.2M). DMAC has less debt than BHVN: DMAC (365K) vs BHVN (36.6M). BHVN (0) and DMAC (0) have equivalent revenues.
BHVNDMACBHVN / DMAC
Capitalization2.33B181M1,288%
EBITDA-877.26M-24.07M3,644%
Gain YTD-38.822-22.099176%
P/E RatioN/AN/A-
Revenue00-
Total Cash486M50.2M968%
Total Debt36.6M365K10,027%
FUNDAMENTALS RATINGS
BHVN vs DMAC: Fundamental Ratings
BHVN
DMAC
OUTLOOK RATING
1..100
4430
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
62
Fair valued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
9048
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHVN's Valuation (55) in the Pharmaceuticals Major industry is in the same range as DMAC (62) in the Biotechnology industry. This means that BHVN’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that DMAC’s stock grew similarly to BHVN’s over the last 12 months.

DMAC's SMR Rating (94) in the Biotechnology industry is in the same range as BHVN (97) in the Pharmaceuticals Major industry. This means that DMAC’s stock grew similarly to BHVN’s over the last 12 months.

DMAC's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for BHVN (90) in the Pharmaceuticals Major industry. This means that DMAC’s stock grew somewhat faster than BHVN’s over the last 12 months.

DMAC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that DMAC’s stock grew similarly to BHVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNDMAC
RSI
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 11 days ago
83%
Declines
ODDS (%)
Bearish Trend 27 days ago
73%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
87%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
79%
View a ticker or compare two or three
Ad is loading...
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSMCX43.380.78
+1.83%
Congress Small Cap Growth Institutional
UGOFX11.330.15
+1.34%
Victory Global Managed Volatility Instl
SROAX12.210.15
+1.24%
Calamos Antetokounmpo Sustainable Eqs A
LONAX14.190.14
+1.00%
Longboard A
PMFYX11.790.10
+0.86%
Victory Pioneer Multi-Asset Income Y

BHVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHVN has been loosely correlated with OCUL. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BHVN jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHVN
1D Price
Change %
BHVN100%
+1.78%
OCUL - BHVN
49%
Loosely correlated
+3.17%
XENE - BHVN
49%
Loosely correlated
+0.50%
CGON - BHVN
48%
Loosely correlated
+4.72%
RCKT - BHVN
48%
Loosely correlated
+1.91%
SYRE - BHVN
47%
Loosely correlated
+3.07%
More